ZYME - Zymeworks Inc.

NYSE - NYSE Delayed Price. Currency in USD
15.06
0.00 (0.00%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close15.06
Open15.05
Bid13.20 x 1400
Ask16.90 x 800
Day's Range14.64 - 15.45
52 Week Range9.71 - 29.00
Volume79,266
Avg. Volume148,321
Market Cap481.051M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Trade prices are not sourced from all markets
  • Benzingalast month

    The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...

  • Business Wirelast month

    Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

    VANCOUVER, British Columbia-- -- Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials Zymeworks to receive milestone payment of US$8.0 million for this second IND submission Lilly is one of eight pharma partners; INDs by others anticipated Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion Zymeworks ...

  • Business Wire2 months ago

    Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.

  • Business Wire2 months ago

    Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

    VANCOUVER, Canada-- -- ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates Complete tumor regressions observed in high and low HER2-expressing models Superior preclinical efficacy compared to approved HER2 ADCs Toxicology results support clinical dosing well above predicted efficacy levels Potential to address unmet need in high and low ...

  • Reuters3 months ago

    BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates

    Nov 27 (Reuters) - Beigene Ltd: * ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND ...

  • Business Wire3 months ago

    Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

    BeiGene acquires exclusive development and commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan), Australia, and New Zealand. The companies will collaborate on joint global development for selected indications. BeiGene also acquires licenses for Zymeworks’ Azymetric™ and EFECT™ platforms to develop and commercialize up to three bispecific antibody therapeutics globally directed to BeiGene's targets.

  • Business Wire3 months ago

    Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

    DUBLIN-- -- ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary ...

  • Business Wire4 months ago

    Zymeworks to Present at Upcoming Investor Conferences

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.

  • Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates

    Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 6.35% and 2.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire4 months ago

    Zymeworks Reports Financial Results for the Third Quarter of 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018.

  • Business Wire4 months ago

    Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium

    VANCOUVER, British Columbia-- -- Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers New and updated data focus on gastroesophageal and other HER2-expressing cancers Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that its abstract describing new data from the Company’s adaptive Phase 1 clinical ...

  • Business Wire4 months ago

    Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology, have entered into a licensing and research collaboration to discover and develop bispecific antibodies targeting cytokine-receptor pathways using Zymeworks’ antibody discovery capabilities and its proprietary Azymetric™ and EFECT™ platforms. LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, while Zymeworks retains rights to develop antibodies in all other therapeutic areas.

  • Business Wire5 months ago

    Zymeworks to Webcast R&D Briefing

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City. Zymeworks’ management team will discuss the Company’s clinical strategy for ZW25, provide an update on its next clinical compound ZW49, and highlight its early-stage platforms and technologies. Mark Pegram, MD, is the Susy Yuan-Huey Hung Professor of Medicine (Oncology) at the Stanford University Medical Center, Director of the Stanford Cancer Institute's Breast Oncology Program, Associate Director of Clinical Research, and Associate Dean of Clinical Research Quality.

  • Business Wire5 months ago

    Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Ladenburg Thalmann 2018 Healthcare Conference taking place October 1-2, 2018 in New York, NY.

  • Business Wire5 months ago

    Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy.

  • Business Wire6 months ago

    Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$2.0 million for Lilly’s submission of an IND application for a bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform. Previously, Zymeworks announced Lilly’s nomination of two bispecific immuno-oncology drug candidates for late-stage preclinical development.

  • Business Wire6 months ago

    Zymeworks to Present at Wells Fargo Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA.

  • Business Wire7 months ago

    Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August 8-9, 2018 in Boston, MA, USA.

  • Business Wire7 months ago

    Zymeworks Reports Financial Results for the Second Quarter of 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2018.

  • Business Wire8 months ago

    Zymeworks Closes Previously Announced Public Offering

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$97.8 million, before deducting the underwriting discounts and commissions and estimated Offering expenses.

  • Business Wire9 months ago

    Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

    Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General and Special Meeting of Shareholders held on June 7, 2018 .

  • Business Wire9 months ago

    Zymeworks Announces Pricing of Public Offering

    Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today the pricing of its previously- announced underwritten public offering (the “Offering”) of 5,400,000 common shares at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$85.1 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, the Company has also granted the underwriters of the Offering a 30-day over-allotment option to purchase up to an additional 810,000 common shares on the same terms and conditions.